MEDtalk: How does early treatment influence the sequence of the following treatment if the disease progresses?

Best Practice Nordic | Jun 2020 | ASCO20 Virtual |

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with non-metastatic castration-resistant prostate cancer.